A detailed history of Old Well Partners, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Old Well Partners, LLC holds 18,038 shares of BGNE stock, worth $2.6 Million. This represents 2.57% of its overall portfolio holdings.

Number of Shares
18,038
Previous 9,638 87.16%
Holding current value
$2.6 Million
Previous $1.74 Million 62.26%
% of portfolio
2.57%
Previous 1.62%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$141.8 - $181.47 $1.19 Million - $1.52 Million
8,400 Added 87.16%
18,038 $2.82 Million
Q4 2023

Feb 14, 2024

SELL
$158.67 - $201.58 $1.51 Million - $1.92 Million
-9,527 Reduced 49.71%
9,638 $1.74 Million
Q3 2023

Nov 14, 2023

SELL
$179.87 - $225.13 $269,805 - $337,695
-1,500 Reduced 7.26%
19,165 $3.45 Million
Q2 2023

Aug 14, 2023

SELL
$178.3 - $266.78 $3.41 Million - $5.1 Million
-19,100 Reduced 48.03%
20,665 $3.68 Million
Q1 2023

May 15, 2023

SELL
$215.53 - $274.5 $581,931 - $741,150
-2,700 Reduced 6.36%
39,765 $8.57 Million
Q4 2022

Feb 14, 2023

BUY
$125.51 - $229.3 $577,346 - $1.05 Million
4,600 Added 12.15%
42,465 $9.34 Million
Q2 2022

Aug 15, 2022

BUY
$121.11 - $216.05 $653,994 - $1.17 Million
5,400 Added 16.63%
37,865 $6.13 Million
Q1 2022

May 16, 2022

BUY
$146.52 - $269.56 $395,604 - $727,812
2,700 Added 9.07%
32,465 $6.12 Million
Q4 2021

Feb 14, 2022

SELL
$248.56 - $389.34 $1.57 Million - $2.45 Million
-6,300 Reduced 17.47%
29,765 $8.06 Million
Q3 2021

Nov 15, 2021

BUY
$249.6 - $403.14 $873,600 - $1.41 Million
3,500 Added 10.75%
36,065 $13.1 Million
Q2 2021

Aug 16, 2021

SELL
$292.75 - $367.01 $204,925 - $256,907
-700 Reduced 2.1%
32,565 $11.2 Million
Q1 2021

May 17, 2021

SELL
$260.64 - $382.12 $3.46 Million - $5.08 Million
-13,288 Reduced 28.54%
33,265 $11.6 Million
Q4 2020

Feb 18, 2021

BUY
$221.31 - $316.61 $10.3 Million - $14.7 Million
46,553 New
46,553 $12 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $14.9B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Old Well Partners, LLC Portfolio

Follow Old Well Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Old Well Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Old Well Partners, LLC with notifications on news.